87 related articles for article (PubMed ID: 25298357)
21. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
22. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
23. Q: Should we use pharmacogenetic testing when prescribing warfarin?
Rouse M; Cristiani C; Teng KA
Cleve Clin J Med; 2013 Aug; 80(8):483-6. PubMed ID: 23908104
[No Abstract] [Full Text] [Related]
24. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.
Grossi E; Podda GM; Pugliano M; Gabba S; Verri A; Carpani G; Buscema M; Casazza G; Cattaneo M
Pharmacogenomics; 2014 Jan; 15(1):29-37. PubMed ID: 24329188
[TBL] [Abstract][Full Text] [Related]
25. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
26. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
Cavallari LH; Nutescu EA
Clin Pharmacol Ther; 2014 Jul; 96(1):22-4. PubMed ID: 24942399
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics of coumarinic oral anticoagulants.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
[TBL] [Abstract][Full Text] [Related]
28. [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].
Stępień E; Wypasek E; Branicka A; Undas A
Kardiol Pol; 2010; 68 Suppl 5():S428-35. PubMed ID: 22134997
[TBL] [Abstract][Full Text] [Related]
29. Role of warfarin pharmacogenetic testing in clinical practice.
Tan GM; Wu E; Lam YY; Yan BP
Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
31. Genotype frequencies of VKORC1 and CYP2C9 in native and Mestizo populations from Mexico, potential impact for coumarin dosing.
Villegas-Torres B; Sánchez-Girón F; Jaramillo-Villafuerte K; Soberón X; Gonzalez-Covarrubias V
Gene; 2015 Mar; 558(2):235-40. PubMed ID: 25560189
[TBL] [Abstract][Full Text] [Related]
32. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.
Kim MJ; Huang SM; Meyer UA; Rahman A; Lesko LJ
J Clin Pharmacol; 2009 Feb; 49(2):138-46. PubMed ID: 19179293
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
34. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
35. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
Schwarz UI; Stein CM
Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
[No Abstract] [Full Text] [Related]
36. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
Loriot MA; Beaune P
Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
[TBL] [Abstract][Full Text] [Related]
37. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
38. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetic variants and vitamin K deficiency: a risk factor or trigger for fibrosing interstitial pneumonias?
Drent M; Wijnen P; Bast A
Curr Opin Pulm Med; 2018 May; 24(3):287-295. PubMed ID: 29538081
[TBL] [Abstract][Full Text] [Related]
40. Evaluating Within-Subject Variability for Narrow Therapeutic Index Drugs.
Jayachandran P; Okochi H; Frassetto LA; Park W; Fang L; Zhao L; Benet LZ
Clin Pharmacol Ther; 2019 Feb; 105(2):411-416. PubMed ID: 30652304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
